# US 2026/0167942 A1 · Adjuvant for intradermal immunization and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0167942 A1
- Document ID: US20260167942A1
- Status: Published application
- Kind: A1
- Application number: 19/536,292
- Filed: 2026-02-11
- Published: 2026-06-18
- Earliest claimed: 2024-09-24
- Assignees: Jiangsu Academy of Agricultural Sciences; Nanjing National Biotechnology Research Institute Co., Ltd.; Guotai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou
- Applicants: Jiangsu Academy of Agricultural Sciences; Nanjing National Biotechnology Research Institute Co., Ltd.; Guotai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou
- Inventors: Bihua DENG; Yu LU; Haiyan WANG; Wenzhu YIN; Fang MA; Yalu ZHU; Yujie ZHOU; Hai XU; Qiurong QI
- Web page: https://patentgrep.com/patent/US20260167942A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/005: from viruses
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16761: Methods of inactivation or attenuation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An adjuvant for intradermal immunization and a use thereof are provided. The adjuvant includes the following components in parts by mass: 10 parts to 25 parts of squalene, 10 parts to 25 parts of sea buckthorn oil, 25 parts to 35 parts of caprylocaproyl polyoxyl-8 glycerides, and 25 parts to 45 parts of Tween 80. The adjuvant for intradermal immunization has a low viscosity, is favorable for injection and absorption, and can significantly enhance the immunization efficacy of a vaccine.

## Claims

### Claim 1

An adjuvant for intradermal immunization, comprising the following components in parts by mass:
10 parts to 25 parts of squalene,
10 parts to 25 parts of sea buckthorn oil,
25 parts to 35 parts of caprylocaproyl polyoxyl-8 glycerides, and
25 parts to 45 parts of Tween 80.

### Claim 2 (depends on 1)

The adjuvant according to claim 1, comprising the following components in parts by mass:
15 parts to 20 parts of the squalene,
15 parts to 20 parts of the sea buckthorn oil,
28 parts to 32 parts of the caprylocaproyl polyoxyl-8 glycerides, and
30 parts to 40 parts of the Tween 80.

### Claim 3 (depends on 1)

A method for preparing an inactivated porcine pseudorabies virus (PRV) vaccine, comprising using the adjuvant according to claim 1.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the inactivated PRV vaccine is a vaccine for the intradermal immunization.

### Claim 5 (depends on 4)

The method according to claim 4, comprising: mixing the adjuvant and an antigen in a volume ratio of 1:(8-10), and conducting emulsification to produce the inactivated PRV vaccine.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the adjuvant comprises the following components in parts by mass:
15 parts to 20 parts of the squalene,
15 parts to 20 parts of the sea buckthorn oil,
28 parts to 32 parts of the caprylocaproyl polyoxyl-8 glycerides, and
30 parts to 40 parts of the Tween 80.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the inactivated PRV vaccine is a vaccine for the intradermal immunization.

### Claim 8 (depends on 4)

The method according to claim 4, comprising: mixing the adjuvant and an antigen in a volume ratio of 1:(8-10), and conducting emulsification to produce the inactivated PRV vaccine;
wherein the adjuvant comprises the following components in parts by mass:
15 parts to 20 parts of the squalene,
15 parts to 20 parts of the sea buckthorn oil,
28 parts to 32 parts of the caprylocaproyl polyoxyl-8 glycerides, and
30 parts to 40 parts of the Tween 80.
